Skip to main content

Table 2 Guideline adherence to, measured as the probability of, prescription of lipid-lowering medications by year

From: Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register

Year Primary prevention Secondary prevention
Crude (%) n = 756,943 Adjusteda (%) n = 238,895 Crude (%) n = 447,423 Adjusteda (%) n = 142,739
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
2007 34.7 (34.3–35.2) 36.2 (34.8–37.5) 70.7 (70.2–71.2) 58.6 (56.8–60.5)
2008 39.0 (38.6–39.4) 40.3 (39.0–41.6) 72.9 (72.4–73.3) 63.0 (61.3–64.7)
2009 42.7 (42.4–43.1) 43.8 (42.4–45.1) 74.7 (74.3–75.1) 66.2 (64.5–67.8)
2010 44.8 (44.5–45.1) 46.3 (44.9–47.6) 74.7 (74.4–75.1) 67.8 (66.2–69.4)
2011 46.8 (46.5–47.1) 46.6 (45.2–48.0) 75.1 (74.8–75.4) 69.1 (67.5–70.7)
2012 47.4 (47.1–47.7) 46.6 (45.2–48.0) 73.6 (73.2–73.9) 67.9 (66.2–69.5)
2013 47.6 (47.3–47.9) 46.6 (45.2–48.0) 71.8 (71.5–72.2) 66.8 (65.1–68.4)
2014 48.3 (48.0–48.6) 46.1 (44.7–47.5) 70.9 (70.5–71.3) 65.9 (64.2–67.5)
  1. aAdjusted for year, county council, type of care, sex, age, HbA1c, eGFR, diabetes duration, diabetes medications, antihypertensives, antiplatelets, blood pressure, microalbuminuria, macroalbuminuria, BMI, physical activity, smoking and cholesterol levels